Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia
Martina Hüttl, Irena Marková, Denisa Miklánková, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11513-11513
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
Θεόδωρος Ανδρουτσάκος, Narjes Nasiri‐Ansari, Athanasios‐Dimitrios Bakasis, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 6, pp. 3107-3107
Open Access | Times Cited: 98
Nrf2 Pathway and Oxidative Stress as a Common Target for Treatment of Diabetes and Its Comorbidities
Michelle Yi, L Cisneros, E.J. Cho, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 821-821
Open Access | Times Cited: 19
Targeting Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Available and Future Pharmaceutical Options
Emmanouil Koullias, Maria Papavdi, John Koskinas, et al.
Cureus (2025)
Open Access | Times Cited: 2
Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary
Annamaria Mascolo, Raffaella Di Napoli, Nunzia Balzano, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 53
Canagliflozin ameliorates the development of NAFLD by preventing NLRP3-mediated pyroptosis through FGF21-ERK1/2 pathway
Shaohan Huang, Beibei Wu, Yingzi He, et al.
Hepatology Communications (2023) Vol. 7, Iss. 3, pp. e0045-e0045
Open Access | Times Cited: 21
Narrative Review of Immunomodulatory and Anti-inflammatory Effects of Sodium-Glucose Cotransporter 2 Inhibitors: Unveiling Novel Therapeutic Frontiers
Sul A Lee, Leonardo V. Riella
Kidney International Reports (2024) Vol. 9, Iss. 6, pp. 1601-1613
Open Access | Times Cited: 7
Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders
Arianna Maiorana, Francesco Tagliaferri, Carlo Dionisi‐Vici
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 15
Empagliflozin alters lipid metabolism in the myocardium and liver in a prediabetes model with severe dyslipidemia
Denisa Miklánková, Irena Marková, Martina Hüttl, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 3
Current Evidence on SGLT‐2 Inhibitors in Prediabetes: A Review of Preclinical and Clinical Data
Fariba Pourkarim, Taher Entezari‐Maleki, Haleh Rezaee
The Journal of Clinical Pharmacology (2025)
Closed Access
Empagliflozin Alleviates Hepatic Steatosis and Oxidative Stress via the NRF1 Pathway in High-Fat Diet-Induced Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease
Yu Jung Heo, Jieun Park, Nami Lee, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 9, pp. 4054-4054
Open Access
Tannic acid- and N-acetylcysteine-chitosan-modified magnetic nanoparticles reduce hepatic oxidative stress in prediabetic rats
Małgorzata Świętek, Irena Marková, Hana Malínská, et al.
Colloids and Surfaces B Biointerfaces (2024) Vol. 235, pp. 113791-113791
Open Access | Times Cited: 3
Hepatoprotective and cardioprotective effects of empagliflozin in spontaneously hypertensive rats fed a high-fat diet
Silvie Hojná, Hana Malínská, Martina Hüttl, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116520-116520
Open Access | Times Cited: 3
Beneficial Effects of Empagliflozin Are Mediated by Reduced Renal Inflammation and Oxidative Stress in Spontaneously Hypertensive Rats Expressing Human C-Reactive Protein
Hana Malínská, Martina Hüttl, Irena Marková, et al.
Biomedicines (2022) Vol. 10, Iss. 9, pp. 2066-2066
Open Access | Times Cited: 14
Sodium Glucose Cotransporter-2 Inhibitors: Spotlight on Favorable Effects on Clinical Outcomes beyond Diabetes
Věra Čertíková Chábová, Oskar Zakiyanov
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 5, pp. 2812-2812
Open Access | Times Cited: 12
Empagliflozin ameliorates liver fibrosis in NASH rat model via targeting hepatic NF-κB/SOX9/OPN signaling and osteocalcin level
Mohamed M. Elseweidy, Abdelmoneim A. Ali, Sara M. Hassanin, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2023) Vol. 397, Iss. 5, pp. 3449-3459
Open Access | Times Cited: 7
Biomarkers for Assessing Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus on Sodium–Glucose Cotransporter 2 Inhibitor Therapy
Farah Khaznadar, Ana G. Petrovic, Omar Khaznadar, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 20, pp. 6561-6561
Open Access | Times Cited: 5
Hypolipidemic Effects of Beetroot Juice in SHR-CRP and HHTg Rat Models of Metabolic Syndrome: Analysis of Hepatic Proteome
Jan Šilhavý, Petr Mlejnek, Miroslava Šimáková, et al.
Metabolites (2023) Vol. 13, Iss. 2, pp. 192-192
Open Access | Times Cited: 4
Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon‐like peptide 1
Nitin Deshmukh, M. S. Kalshetti, Mohan Patil, et al.
Clinical and Experimental Pharmacology and Physiology (2024) Vol. 51, Iss. 5
Closed Access | Times Cited: 1
Gliflozins in the Treatment of Non-diabetic Experimental Cardiovascular Diseases
Ivana Vaněčková, Josef Zicha
Physiological Research (2024), Iss. Suppl 1, pp. S377-S387
Open Access | Times Cited: 1
Model organisms for investigating the functional involvement of NRF2 in non-communicable diseases.
Ana I. Rojo, Brigitta Buttari, Susana Cadenas, et al.
Redox Biology (2024) Vol. 79, pp. 103464-103464
Open Access | Times Cited: 1
Empagliflozin Ameliorates Progression From Prediabetes to Diabetes and Improves Hepatic Lipid Metabolism: A Systematic Review
Md Fahad Hossain, Nawsheen A Khan, Afroza Rahman, et al.
Cureus (2022)
Open Access | Times Cited: 6
Underestimated Prediabetic Biomarkers: Are We Blind to Their Strategy?
Carla Luís, Raquel Soares, Pilar Baylina, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 4
Protective mechanism and clinical application of SGLT2 inhibitors in patients with type 2 diabetes mellitus complicated with abnormal liver function
Zhao Yun-hui
Deleted Journal (2024) Vol. 1, Iss. 1, pp. 35-45
Open Access
Interaction of fetuin-A with obesity related insulin resistance and diabetes mellitus
Yıldız Öner-İyidoğan, Hikmet Koçak
Turkish Journal of Biochemistry (2024)
Open Access
Spontaneous nonsense mutation in the tuftelin 1 gene is associated with abnormal hair appearance and amelioration of glucose and lipid metabolism in the rat
Jan Šilhavý, Petr Mlejnek, Miroslava Šimáková, et al.
Physiological Genomics (2023) Vol. 56, Iss. 1, pp. 65-73
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top